Question 1
This question is based on the Advance Notice Article ‘Development of therapeutic antibodies for the treatment of disease’.
Scientists can combine antibody fragments using phage display to produce many different antibodies, each specific to a different antigen.
Using the abbreviations from Fig. 1 in the Advance Notice Article, explain how combining antibody fragments allows scientists to produce many different antibodies, each specific to a different antigen.
[2]
The B cell receptor is an IgG molecule with the same structure as the human IgG shown in Fig. 1 in the Advance Notice Article.
Use an abbreviation from Fig. 1 to identify the part of the B cell receptor that will be attached to the cell surface membrane of a B cell.
[1]
Explain why mouse monoclonal antibodies (mAbs) have been largely replaced as therapeutic antibodies by humanised or fully human mAbs.
[2]
Explain why the Fab and scFv antibody fragments shown in Fig. 1 are effective as neutralizing or agglutinating antibodies but are less effective as opsonins or in activation of complement.
[2]
Describe how therapeutic mAbs can be used in cancer treatment.
[3]
The cost of treating a patient with advanced cancer using therapeutic mAbs can be extremely high. In some cases, the treatment can increase survival time by just a few months.
Pharmaceutical companies justify the high cost of treatment based on the high costs of developing and testing therapeutic mAbs.
Discuss whether the use of therapeutic mAbs to treat cancer justifies the high costs.
[3]
* Describe the role of T and B lymphocytes in the development of long-term immunity.
Additional answer space if required.
[6]